Shots:

• The P-III D8110C00001 study involves assessing AZD1222 vs PBO in 32-449 participants in a ratio (2:1) aged ≥18yrs. across 88 trial centers in the US- Peru and Chile to prevent COVID-19. his primary efficacy analysis included the accrual of 190 symptomatic cases of COVID-19 from total participants
• The study showed 76% efficacy against symptomatic COVID-19- 85% efficacy in aged ≥65yrs. as its 1EPs and showed 100% efficacy against severe disease and hospitalization in 2EPs. The vaccine was well tolerated with no safety concerns
• The company will submit EUA to US FDA and also submit the primary analysis for peer-reviewed publication in the coming weeks

 ­ Ref: AstraZeneca | Image: Mint